Upon infection, SARS-CoV-2 (blue) uses host machinery to produce polyproteins for replication. The viral main protease (yellow) plays a key role in polyprotein cleavage and thus is a potential drug target. Researchers have designed two antiviral compounds that inhibit activity of the main protease to prevent viral replication. Preclinical studies show that these compounds are promising therapeutic candidates.